WeVote
Log In

Bill

Bill

SB 640

Retail Sale of Ephedrine and Related Compounds

2025 Regular Session Introduced by Jonathan Martin

Failed Florida bill would have restricted retail sales of ephedrine compounds to combat methamphetamine manufacturing while maintaining legitimate consumer access to decongestants.

Died in Health Policy
#subjectindex
0
WeVote Research Nonpartisan
Bill Summary · SB 640

Legislative bill overview

SB 640 would have regulated the retail sale of ephedrine and related compounds in Florida, likely establishing purchase limits, age restrictions, or permitting requirements for these stimulant substances. The bill was introduced in February 2025 but died in the Health Policy Committee after being indefinitely postponed in May.

Why is this important

Ephedrine and related compounds (like pseudoephedrine) are common in over-the-counter decongestants but can be misused to manufacture illegal methamphetamine. Regulating their retail sale is a public health measure aimed at reducing drug production while maintaining consumer access to legitimate cold and allergy medications.

Potential points of contention

  • Balance between access and control: Restrictions could inconvenience consumers purchasing legitimate decongestants while potentially just displacing illicit acquisition methods
  • Retail burden: Pharmacies and retailers would bear compliance costs for tracking, verification, and record-keeping requirements
  • Effectiveness questions: Similar regulations in other states show mixed results in actually reducing methamphetamine production, raising concerns about whether restrictions justify their implementation costs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.